stockrow
Saturday 7 November 2026
Export MTNB’s income statement to Excel — free account
Matinas Biopharma Holdings, Inc.
MTNB Healthcare Biotechnology
Matinas Biopharma Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.1 million, down 65.6% from fiscal 2022.
- EPS
- +79.6%
- Free cash flow
- +9.15%
- Total debt
- −54.5%
Quarter to June 2026, against a year earlier
1.19
0.03
+2.59%
Follow MTNB
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
3.67 | 2.77 | 1.15 | 0.60 | |
Current Ratio |
3.78 | 2.79 | 1.32 | 0.85 | |
Net Debt/EBITDA |
3.73 | 2.69 | 1.31 | 0.52 | |
Debt/Assets |
0.11% | 0.07% | 0.09% | 0.15% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.69 | 0.79 | 0.83 | 1.38 | |
Capex/Depreciation |
2.88 | 0.16 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.07) | (4.13) | (3.75) | (4.30) | |
Capex per Share |
0.88 | 0.04 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.18) | (4.09) | (3.75) | (4.30) | |
Cash per Share |
15.13 | 11.09 | 5.73 | 1.90 | |
Shareholders Equity per Share |
17.82 | 13.23 | 7.07 | 4.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.82 | 13.23 | 7.07 | 4.21 | |
Free Cash Flow |
(1.15) | (1.49) | (1.60) | (1.84) | |
Working Capital |
4.16 | 2.61 | 0.69 | (0.21) | |
Capital Expenditures |
0.32 | 0.02 | — | — | |
Net Current Asset Value |
2.42 | 1.70 | (0.04) | (0.47) | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Payables |
0.21 | 0.21 | 0.50 | 0.51 | |
Average Assets |
15.14 | 9.92 | 8.95 | 7.42 | |
Average Common Equity |
11.12 | 6.21 | 4.65 | 4.74 |
Columns are period end dates · fundamentals updated 2 Nov 2026